Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
10x Genomics, Inc. Banner

10x Genomics, Inc.

TXG Stock Analysis

Page title

Section title

About 10x Genomics, Inc.

Medical - Healthcare Information Services
Healthcare

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products...

10x Genomics, Inc. Key Metrics

Market Cap
$2B
52 Weeks Low
$12.95
52 Weeks High
$57.90
P/B
2.22x
P/E
-8.81x
P/S
2.56x

Upcoming Events

    TXG Analyst Forecasts



    TXG Financials

    TXG Income Statement Key Metrics

    • Revenue(TTM)629.74 M
    • Gross Profit(TTM)414.92 M
    • EBITDA(TTM)-131.06 M
    • Net Income(TTM)-182.55 M
    • EPS Diluted(TTM)-1.53

    Decode TXG's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    TXG earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of TXG (0.662) is higher than the average of its peers (0.648).

    Net Profit Margin vs Peers

    Net profit margin ratio of TXG (-0.412) is higher than the average of its peers (-0.955).

    TXG Return on Equity

    See how efficiently TXG generates profit for it's shareholders.

    -34.42%

    10
    0
    100
    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of TXG (-0.344) is higher than the average of its peers (-0.799).

    Return on Equity Growth

    TXG's Return on Equity has shown poor growth over the past 10 years, increasing by only -10.91%.

    TXG Revenue Growth

    See how TXG has grown it's revenue over the past 10 years.


    Revenue Growth

    TXG's revenue has grown significantly over the past 10 years, increasing by over 36.22%.